

Khalid Shoumariyeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1422344/publications.pdf>

Version: 2024-02-01

29
papers

961
citations

471371

17
h-index

580701

25
g-index

29
all docs

29
docs citations

29
times ranked

1347
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
2	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	2.2	101
3	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. <i>Nature Communications</i> , 2020, 11, 1659.	5.8	92
4	MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2846-2856.	0.8	82
5	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	70
6	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	2.7	47
7	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6436.	5.8	45
8	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	2.0	42
9	Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. <i>Haematologica</i> , 2020, 105, 2872-2878.	1.7	40
10	Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. <i>Lancet Haematology</i> , 2021, 8, e194-e204.	2.2	39
11	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , 2020, 34, 1090-1101.	3.3	34
12	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. <i>Leukemia</i> , 2019, 33, 1124-1134.	3.3	29
13	Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany. <i>Cancer Medicine</i> , 2020, 9, 8412-8422.	1.3	29
14	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , 2022, 36, 516-524.	3.3	29
15	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , 2021, 13, 1151.	1.7	27
16	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , 2021, 11, 292-303.	4.6	26
17	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019, 4, e000583.	2.0	22
18	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1705-1712.e4.	2.0	13

#	ARTICLE	IF	CITATIONS
19	Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. <i>Journal of Clinical Investigation</i> , 2020, 130, 2827-2844.	3.9	8
20	Blastic transformation of <i>BCR-ABL1</i> positive chronic myeloid leukaemia through acquisition of <i>CBFB-MYH11</i> and mutant <i>KIT</i> . <i>British Journal of Haematology</i> , 2020, 190, e339-e343.	1.2	5
21	Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model. <i>Leukemia</i> , 2020, 34, 3242-3255.	3.3	4
22	A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette. <i>Oncogene</i> , 2020, 39, 1904-1913.	2.6	3
23	Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. <i>BMC Cancer</i> , 2021, 21, 173.	1.1	3
24	Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, , 81.	1.2	2
25	Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 148, 331.	1.2	2
26	Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab. <i>Annals of Hematology</i> , 2021, 100, 1637-1640.	0.8	1
27	Metabolic Reprogramming Overcomes T Cell Inhibition By AML Cells. <i>Blood</i> , 2018, 132, 3328-3328.	0.6	0
28	Checkpoint Inhibition in CSF3R Mutated Chronic Neutrophilic Leukemia. <i>Blood</i> , 2018, 132, 3056-3056.	0.6	0
29	The Fanconi Anemia-Associated Protein NIPA Is Essential for the Nuclear Abundance of FANCD2. <i>Blood</i> , 2019, 134, 3741-3741.	0.6	0